Publication details

Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.

Investor logo

LADUNGOVÁ Adriana BUŠA Daniel LODHI Yusuf HÝL Jan ČULEN Martin ŠMÍDA Michal

Year of publication 2023
Type Conference abstract
MU Faculty or unit

Central European Institute of Technology

Attached files
Description Acute myeloid leukemia (AML) is a malignant disease derived from the bone marrow precursors of myeloid lineage Treatment options are rather limited, primarily based on chemotherapy, and often result in disease progression Recently, venetoclax-based therapies have transformed the frontline regimens of elderly patients and patients unfit for intensive chemotherapy. Despite its promising outcomes in clinical studies, multiple resistant subclones evolved during the treatment acting as a barrier in disease regression Understanding the venetoclax-resistance mechanisms and detecting the major determinants could reveal previously unrecognized novel perspectives for therapeutic strategies to improve patients’ outcomes. Moreover, performing high-throughput screenings with clinically approved drugs could reveal novel treatment options for resistant subclones of AML.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info